CN102159574A - 三-环吡唑并吡啶激酶抑制剂 - Google Patents

三-环吡唑并吡啶激酶抑制剂 Download PDF

Info

Publication number
CN102159574A
CN102159574A CN2009801367212A CN200980136721A CN102159574A CN 102159574 A CN102159574 A CN 102159574A CN 2009801367212 A CN2009801367212 A CN 2009801367212A CN 200980136721 A CN200980136721 A CN 200980136721A CN 102159574 A CN102159574 A CN 102159574A
Authority
CN
China
Prior art keywords
independently
optionally
substituted
compound
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801367212A
Other languages
English (en)
Chinese (zh)
Inventor
J-M·希门尼斯
J·斯塔德利
R·克内格特尔
L·塞蒂莫
C·戴维斯
D·弗雷斯
P·科利尔
G·布伦奇利
D·博亚尔
A·米勒
H·特温
S·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN102159574A publication Critical patent/CN102159574A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2009801367212A 2008-07-23 2009-07-22 三-环吡唑并吡啶激酶抑制剂 Pending CN102159574A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US8291908P 2008-07-23 2008-07-23
US61/082,919 2008-07-23
US11603208P 2008-11-19 2008-11-19
US61/116,032 2008-11-19
US14010008P 2008-12-23 2008-12-23
US61/140,100 2008-12-23
US16315209P 2009-03-25 2009-03-25
US61/163,152 2009-03-25
PCT/US2009/051437 WO2010011772A2 (en) 2008-07-23 2009-07-22 Tri-cyclic pyrazolopyridine kinase inhibitors

Publications (1)

Publication Number Publication Date
CN102159574A true CN102159574A (zh) 2011-08-17

Family

ID=41137604

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801367212A Pending CN102159574A (zh) 2008-07-23 2009-07-22 三-环吡唑并吡啶激酶抑制剂

Country Status (12)

Country Link
EP (1) EP2318408B1 (OSRAM)
JP (2) JP2011529066A (OSRAM)
KR (1) KR20110033299A (OSRAM)
CN (1) CN102159574A (OSRAM)
AR (1) AR074171A1 (OSRAM)
AU (1) AU2009274027A1 (OSRAM)
BR (1) BRPI0916295A2 (OSRAM)
CA (1) CA2731432A1 (OSRAM)
IL (1) IL210822A0 (OSRAM)
MX (1) MX2011000843A (OSRAM)
TW (1) TW201018680A (OSRAM)
WO (1) WO2010011772A2 (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103003273A (zh) * 2010-01-27 2013-03-27 沃泰克斯药物股份有限公司 吡唑并吡啶激酶抑制剂
CN110662544A (zh) * 2017-03-24 2020-01-07 纳诺森公司 具有有用的药学应用的稠合三唑并嘧啶化合物
CN111032045A (zh) * 2017-08-15 2020-04-17 安吉奥斯医药品有限公司 用于治疗血液病症的丙酮酸激酶激活剂
CN111620866A (zh) * 2019-02-27 2020-09-04 南京药石科技股份有限公司 一种顺式-7,7-二氟-六氢-1H 吡咯并[3,4-c]吡啶衍生物及其制备方法
WO2024222680A1 (zh) * 2023-04-24 2024-10-31 北京宇繁科技有限责任公司 一种map4k4抑制剂及其制备方法和应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3140759B2 (ja) 1990-04-02 2001-03-05 キンセキ株式会社 弾性表面波素子の製造方法
JP3362860B2 (ja) 1991-01-09 2003-01-07 大日本印刷株式会社 表面弾性波素子の製造方法
JP2013518114A (ja) * 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピリミジンキナーゼ阻害剤
AU2011209649A1 (en) * 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
CN102858769A (zh) * 2010-01-27 2013-01-02 沃泰克斯药物股份有限公司 吡唑并吡啶激酶抑制剂
US20130096160A1 (en) * 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
KR20130128435A (ko) 2010-12-16 2013-11-26 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
CN103492382A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013037390A1 (en) * 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) * 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) * 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013060636A1 (en) * 2011-10-25 2013-05-02 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013167403A1 (en) * 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
WO2013184985A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2014181813A1 (ja) * 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
JP6878316B2 (ja) * 2015-06-19 2021-05-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
JP6828271B2 (ja) 2016-05-18 2021-02-10 ソニー株式会社 通信装置、通信方法、プログラム、および、通信システム
KR20240157788A (ko) * 2022-02-08 2024-11-01 테라스, 인크. 암 및 기타 적응증의 치료에 사용하기 위한 적어도 4개의 환에 의해서 형성된 t 구조를 갖는 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10222550A1 (de) * 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
MXPA05001688A (es) * 2002-08-12 2005-04-19 Sugen Inc 3-pirrolil-piridopirazoles y 3-pirrolil-indazoles como inhibidores de cinasa novedosos.
US7507826B2 (en) * 2004-03-30 2009-03-24 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
WO2005103050A2 (en) * 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
BRPI0610828A2 (pt) * 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103003273A (zh) * 2010-01-27 2013-03-27 沃泰克斯药物股份有限公司 吡唑并吡啶激酶抑制剂
CN110662544A (zh) * 2017-03-24 2020-01-07 纳诺森公司 具有有用的药学应用的稠合三唑并嘧啶化合物
CN111032045A (zh) * 2017-08-15 2020-04-17 安吉奥斯医药品有限公司 用于治疗血液病症的丙酮酸激酶激活剂
CN111032045B (zh) * 2017-08-15 2023-08-15 安吉奥斯医药品有限公司 用于治疗血液病症的丙酮酸激酶激活剂
CN111620866A (zh) * 2019-02-27 2020-09-04 南京药石科技股份有限公司 一种顺式-7,7-二氟-六氢-1H 吡咯并[3,4-c]吡啶衍生物及其制备方法
WO2024222680A1 (zh) * 2023-04-24 2024-10-31 北京宇繁科技有限责任公司 一种map4k4抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
WO2010011772A3 (en) 2010-04-29
EP2318408B1 (en) 2016-02-17
BRPI0916295A2 (pt) 2019-09-24
AR074171A1 (es) 2010-12-29
KR20110033299A (ko) 2011-03-30
JP2014208710A (ja) 2014-11-06
JP5931976B2 (ja) 2016-06-08
CA2731432A1 (en) 2010-01-28
WO2010011772A2 (en) 2010-01-28
AU2009274027A1 (en) 2010-01-28
EP2318408A2 (en) 2011-05-11
JP2011529066A (ja) 2011-12-01
TW201018680A (en) 2010-05-16
IL210822A0 (en) 2011-04-28
MX2011000843A (es) 2011-04-11

Similar Documents

Publication Publication Date Title
CN102131807B (zh) 吡唑并吡啶激酶抑制剂
JP5931976B2 (ja) 三環式ピラゾロピリジンキナーゼ阻害剤
EP2328896B1 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
JP5542287B2 (ja) ピラゾロピリジンキナーゼ阻害剤
CN101903384A (zh) 作为蛋白激酶Cθ抑制剂的[1H-吡唑并[3,4-B]吡啶-4-基]-苯基或-吡啶-2-基衍生物
JP5769733B2 (ja) ピラゾロピリジンキナーゼ阻害剤
JP2013518112A (ja) ピラゾロピリジンキナーゼ阻害剤
CN102159546A (zh) 氨基吡啶激酶抑制剂
CN102869663A (zh) 吡唑并吡嗪激酶抑制剂
JP2013518114A (ja) ピラゾロピリミジンキナーゼ阻害剤
HK1156617A (en) Tri-cyclic pyrazolopyridine kinase inhibitors
HK1179267A (en) Pyrazolopyrazine kinase inhibitors
HK1156026B (en) Pyrazolopyridine kinase inhibitors
HK1156024A (en) Tri-cyclic pyrazolopyridine kinase inhibitors
HK1156025A (en) Pyrazolopyridine kinase inhibitors
HK1180323A (en) Pyrazolopyrimidine kinase inhibitors
HK1183478A (en) Pyrazolopyridine kinase inhibitors
HK1168595A (en) 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
AU2015201376A1 (en) Pyrazolopyridine kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1156617

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110817

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1156617

Country of ref document: HK